1. Home
  2. NAOV vs CERO Comparison

NAOV vs CERO Comparison

Compare NAOV & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAOV
  • CERO
  • Stock Information
  • Founded
  • NAOV 2003
  • CERO 2017
  • Country
  • NAOV United States
  • CERO United States
  • Employees
  • NAOV N/A
  • CERO N/A
  • Industry
  • NAOV Industrial Specialties
  • CERO
  • Sector
  • NAOV Health Care
  • CERO
  • Exchange
  • NAOV Nasdaq
  • CERO Nasdaq
  • Market Cap
  • NAOV 3.1M
  • CERO 3.1M
  • IPO Year
  • NAOV N/A
  • CERO N/A
  • Fundamental
  • Price
  • NAOV $3.04
  • CERO $0.70
  • Analyst Decision
  • NAOV
  • CERO
  • Analyst Count
  • NAOV 0
  • CERO 0
  • Target Price
  • NAOV N/A
  • CERO N/A
  • AVG Volume (30 Days)
  • NAOV 2.3M
  • CERO 1.0M
  • Earning Date
  • NAOV 05-14-2025
  • CERO 05-16-2025
  • Dividend Yield
  • NAOV N/A
  • CERO N/A
  • EPS Growth
  • NAOV N/A
  • CERO N/A
  • EPS
  • NAOV N/A
  • CERO N/A
  • Revenue
  • NAOV $2,558,000.00
  • CERO N/A
  • Revenue This Year
  • NAOV N/A
  • CERO N/A
  • Revenue Next Year
  • NAOV N/A
  • CERO N/A
  • P/E Ratio
  • NAOV N/A
  • CERO N/A
  • Revenue Growth
  • NAOV 227.79
  • CERO N/A
  • 52 Week Low
  • NAOV $1.92
  • CERO $0.65
  • 52 Week High
  • NAOV $13.97
  • CERO $255.00
  • Technical
  • Relative Strength Index (RSI)
  • NAOV 40.38
  • CERO 24.94
  • Support Level
  • NAOV $2.90
  • CERO $0.66
  • Resistance Level
  • NAOV $4.69
  • CERO $0.80
  • Average True Range (ATR)
  • NAOV 0.66
  • CERO 0.12
  • MACD
  • NAOV 0.02
  • CERO 0.03
  • Stochastic Oscillator
  • NAOV 32.54
  • CERO 7.97

About NAOV NanoVibronix Inc.

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Share on Social Networks: